Primed blood cells enhance efficacy of cell therapy in myocardial infarction

In News by

Researchers from Seoul University, Korea have provided preliminary evidence for the added therapeutic efficacy of Activated Platelet Supernatant (APS) primed mobilized peripheral blood mononuclear cells (mobPBMCs) in treating myocardial infarction (MI).

During the past decade, cell therapy approaches have been applied to various diseases, including MI. One of the most promising benefits of cell therapy in MI, is the potential for cardiac tissue regeneration to reverse the tissue loss underlying heart failure and cardiac injury. However, the low efficacy rates have limited its potential as a therapeutic tool.

The present study by Prof. Hyo-Soo Kim and team sought to address this concern. The team used APS of rats to prime mobPBMCs and investigated the efficacy of cell therapy in a rat MI model. The study revealed that ex vivo APS priming can enhance the wound healing and tissue regeneration potential of mobPBMCs and therefore, this strategy of APS-priming may be a promising method for cell-based therapy of MI in the future. However, additional studies are required to optimize the APS constituents and design methods to obtain the best APS, before this can be tested in humans.

Source: Kang J et al. Priming mobilized peripheral blood mononuclear cells with the ‘Activated Platelet Supernatant’ enhances the efficacy of cell therapy for myocardial infarction of rats.Cardiovascular therapeutics (May 2016).